Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a doubleblind, randomised withdrawal phase

RCT (n=137) reports more patients maintained a complete response (mean 24-h urinary free cortisol concentration of ≤ULN) with osilodrostat, an oral inhibitor of of aldosterone synthase, compared with placebo at week 34 (31 [86%] vs 10 [29%]; OR 13.7 [95% CI 3.7–53.4]; p<0.0001).

SPS commentary:

In the UK, osilodrostat is licensed for treatment of Cushing's disease but not yet launched.


The Lancet Diabetes & Endocrinology